His scientific interests lie mostly in Immunology, Mucopolysaccharidosis, Genetic enhancement, Mucopolysaccharidosis VII and Endocrinology. His biological study spans a wide range of topics, including Factor IX and Bioinformatics. His work carried out in the field of Mucopolysaccharidosis brings together such families of science as Lysosomal storage disease, Spleen and Central nervous system.
His Genetic enhancement research incorporates elements of Target organ, Gene replacement, Lysosomal storage disorders, Viral vector and Morris water navigation task. His studies in Mucopolysaccharidosis VII integrate themes in fields like Ratón and Enzyme replacement therapy. His Endocrinology study integrates concerns from other disciplines, such as Internal medicine and Glucocorticoid receptor.
Mark S. Sands mainly focuses on Immunology, Lysosomal storage disease, Genetic enhancement, Mucopolysaccharidosis and Pathology. Mark S. Sands has included themes like Galactosylceramidase, Transplantation, Leukodystrophy and Enzyme replacement therapy in his Immunology study. In his study, which falls under the umbrella issue of Lysosomal storage disease, Neuronal ceroid lipofuscinosis and Neuroscience is strongly linked to Batten disease.
His Genetic enhancement research includes elements of Adeno-associated virus, Virus, Virology, Central nervous system and Viral vector. His Mucopolysaccharidosis study incorporates themes from Mucopolysaccharidosis VII, Sly syndrome, Endocrinology and Spleen. His Pathology research includes themes of Retinal and Anatomy.
Mark S. Sands mostly deals with Immunology, Lysosomal storage disease, Enzyme replacement therapy, Galactosylceramidase and Leukodystrophy. The study incorporates disciplines such as Genetic enhancement and Transplantation in addition to Immunology. His Genetic enhancement research is multidisciplinary, incorporating perspectives in Virus, Virology, Adeno-associated virus and Central nervous system.
His Lysosomal storage disease research is multidisciplinary, incorporating perspectives in Batten disease, PPT1 and Infantile neuronal ceroid lipofuscinosis. His research integrates issues of Immune system, Mucopolysaccharidosis and Pharmacology in his study of Enzyme replacement therapy. His Mucopolysaccharidosis research incorporates themes from Mucopolysaccharidosis VII, Hepatosplenomegaly and Pediatrics.
Mark S. Sands spends much of his time researching Lysosomal storage disease, Leukodystrophy, Krabbe disease, Galactosylceramidase and Immunology. His Lysosomal storage disease research includes themes of Batten disease, Enzyme replacement therapy, PPT1 and Infantile neuronal ceroid lipofuscinosis. The various areas that Mark S. Sands examines in his Enzyme replacement therapy study include Mucopolysaccharidosis VII, Family history, Mucopolysaccharidosis, Hepatosplenomegaly and Pediatrics.
Mark S. Sands interconnects Metabolic disorder and Genetic enhancement in the investigation of issues within Immunology. His Genetic enhancement research integrates issues from Virus and Virology. His Internal medicine study frequently draws connections between adjacent fields such as Endocrinology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
AAV Vector Integration Sites in Mouse Hepatocellular Carcinoma
Anthony Donsante;Daniel G. Miller;Yi Li;Carole Vogler.
Gene therapy for lysosomal storage diseases.
Mark S. Sands;Beverly L. Davidson.
Molecular Therapy (1998)
CMV-β-Actin Promoter Directs Higher Expression from an Adeno-Associated Viral Vector in the Liver than the Cytomegalovirus or Elongation Factor 1α Promoter and Results in Therapeutic Levels of Human Factor X in Mice
Lingfei Xu;Thomas Daly;Cuihua Gao;Terence R. Flotte.
Human Gene Therapy (2001)
Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer.
John H. Wolfe;Mark S. Sands;Jane E. Barker;Babette Gwynn.
Background mutations in parental cells account for most of the genetic heterogeneity of induced pluripotent stem cells.
Margaret A. Young;David E. Larson;Chiao Wang Sun;Daniel R. George.
Cell Stem Cell (2012)
ENZYME REPLACEMENT THERAPY FOR MURINE MUCOPOLYSACCHARIDOSIS TYPE VII
M S Sands;C Vogler;J W Kyle;J H Grubb.
Journal of Clinical Investigation (1994)
Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease
Thomas M. Daly;Carole Vogler;Beth Levy;Mark E. Haskins.
Proceedings of the National Academy of Sciences of the United States of America (1999)
In vivo distribution of human adipose-derived mesenchymal stem cells in novel xenotransplantation models.
Todd E. Meyerrose;Daniel A. De Ugarte;A. Alex Hofling;Phillip E. Herrbrich.
Stem Cells (2007)
Marrow Stromal Cells and Osteoclast Precursors Differentially Contribute to TNF-α-Induced Osteoclastogenesis In Vivo
Hideki Kitaura;Mark S. Sands;Kunihiko Aya;Ping Zhou.
Journal of Immunology (2004)
Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged beta-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice.
Thomas M. Daly;Torayuki Okuyama;Carole Vogler;Mark E. Haskins.
Human Gene Therapy (1999)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: